Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation
In this role, Neeraj will be responsible for crafting strategy, driving profitable growth through organic and inorganic models, expanding client base
These findings follow positive Phase 3 results presented earlier this year
First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
Subscribe To Our Newsletter & Stay Updated
